

CERP Honoring 10 CERPIs for its 10th Anniversary

ChromaDex is celebrating the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™) beginning in June and continuing throughout the year. CERP™ was established in 2013 by Frank Jaksch, ChromaDex Co-Founder and Executive Chairman, as a program to provide material and technical support for academic, government, and industry investigators interested in our ingredients for research purposes. To mark this momentous occasion, we are highlighting 10 scientists out of the over 235 independent investigators in our program for their contributions to advancing the science of our products. Selected through a careful nomination process, the ten CERPIs, featured here, are among the top investigators who have helped shape the program into what it is today. We would like to commend and spotlight the impact these individuals have made in the advancement of scientific knowledge. Listed in alphabetical order.



**Vilhelm Bohr, MD,
PhD, D. SC***
University of
Copenhagen; NIA Retired



**Charles Brenner,
PhD***
City of Hope



**Evandro F. Fang,
PhD**
University of Oslo



John M. Gonzalez, PhD
University of Georgia



Eija Pirinen, PhD
University of Oulu



Maria P. Portillo, PhD
University of the Basque
Country



Douglas Seals, PhD
University of Colorado,
Boulder



Paul M. Yen, MD
Duke-NUS Medical School


Honorable Mentions



Brunie Felding, PhD*
Scripps Research Institute



Robert Mankowski, PhD
University of Florida



Philip Redpath, PhD**
ChromaDex, Inc.

Special Honoree

Please note: Selection as a CERP 10 for 10 awardee was approved by the investigator and/or their institution. Such selection does not suggest – whether express or implied – an endorsement of ChromaDex or its products by the above-named individuals or any investigator included in CERP.

* Members of the ChromaDex SAB

** ChromaDex employee

In This Issue

- CERP 10th anniversary
- NAD+ Science and News We Are Talking About
- Upcoming Conferences



Reminder


Do not forget to submit your progress report every six (6) months, or as stipulated in your MTA. An updated progress report is required when requesting additional material or submitting an MTA amendment. We will provide you with a progress report form to simplify the process.

Request forms at cerp@chromadex.com for:


- Abstract, manuscript, poster, or presentation slides submissions
- Bulk or clinical material requests
- Requesting an amendment

A Decade of CERP

Since its founding ten years ago, CERP™ has propelled research and grown into an industry leading example of support for research investigators in NAD science. Throughout its tenure CERP™ has developed over 275 global material transfer agreements across over 200 institutions in more than 30 countries (Figure 1). Over 95% of these agreements were investigator-initiated and third-party funded, a strategy to affirm the public of our commitment to scientific integrity and investigator independence. Until recently, all research materials were provided free of cost, which resulted in more than \$4,500,000 USD market value in material donations. This represents over \$95,000,000 USD in estimated research value. The program has also resulted in a strong patent portfolio for NR with an impressive array of over 40 granted patents relating to Niagen®, ChromaDex's patented nicotinamide riboside (NR), in addition to other NAD+ precursors.



In January 2022, CERP™ celebrated its 100th published peer-reviewed study on Niagen and other materials. This study joins the growing body of clinical and preclinical evidence supporting health benefits of NR supplementation. To date, CERP™ now has over 150 peer-reviewed publications including 27 clinical manuscripts on Niagen (Figure 2). This accounts for approximately 40% of all NR studies worldwide that have been supported through our program (Figure 3). Additionally, over 70% of registered ongoing or completed NR trials listed on the registry clinicaltrials.gov use Niagen NR.



Interested in
studying
aesthetics?

Let us know!

Contact us at
CERP@ChromaDex.com

Do You Want Your
Voice Heard?

As always, the CERP team is immensely interested in hearing the opinions and viewpoints of our investigators.


Therefore, we are happy to report that The CERPI Communiqué will now accept Letters to the Editor.

CERPIs who wish to write a letter may email cerp@chromadex.com.

In the email, please be sure to clearly indicate your title, institution, and which article the letter is referring to.

The letter should preferably contain no more than 500 words.

We look forward to hearing from you!



Did we miss your publication?


Please be sure to send your manuscripts to cerp@chromadex.com prior to submission and keep us updated as you move through the publication process.

Want to easily introduce CERP™ to your scientific colleagues? Feel free to share this newsletter or have them scan our QR code.



Figure 3

NR publications by year



We're proud to champion real science and real results, and excited to continue supporting the exceptional investigators in their future research endeavors through CERP™.

NAD+ Science & News We Are Talking About

Q2 Publications

- [Nicotinamide riboside and dietary restriction effects on gut microbiota, liver inflammatory and morphological markers in cafeteria diet-induced obesity in rats.](#)
- [Nicotinamide riboside rescues dysregulated glycolysis and fatty acid \$\beta\$ -oxidation in a human hepatic cell model of Citrin deficiency.](#)
- [Nicotinamide Riboside Improves Enteric Neuropathy in Streptozocin-Induced Diabetic Rats Through Myenteric Plexus Neuroprotection.](#)
- [Nicotinamide Adenine Dinucleotide Precursor Suppresses Hepatocellular Cancer Progression in Mice.](#)
- [Oral supplementation of nicotinamide riboside alters intestinal microbial composition in rats and mice, but not humans.](#)
- [NAD depletion mediates cytotoxicity in human neurons with autophagy deficiency.](#)
- [Remission of social behavior impairment by oral administration of a precursor of NAD in CD157, but not in CD38, knockout mice.](#)
- [Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease.](#)

Other News

- [NAD Supplement Alleviates Intestinal Barrier Injury Induced by Ethanol Via Protecting Epithelial Mitochondrial Function.](#)
- [Boosting NAD ameliorates hematopoietic impairment linked to short telomeres in vivo.](#)
- [Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease.](#)
- [Loss of smelling is an early marker of aging and is associated with inflammation and DNA damage in C57BL/6J mice.](#)
- [Nicotinamide Riboside for Progressing Glaucoma: A Double-blind, Parallel Group, Randomized, Placebo-controlled Trial – A Report on Neuroenhancement](#)

Newly Registered Clinical Trials

- [Effect of nicotinamide riboside supplementation in dilated cardiomyopathy patients](#)

Sorry We Missed You at the ISSN Conference!



Recently, Jun Kwon, CERP Science Manager for the USA, China, & Korea, achieved the Certified Sports Nutritionist certification from the International Society of Sports Nutrition (ISSN), a credential that demonstrates a comprehensive understanding of the role of nutrition in both acute and chronic adaptive responses to exercise. This certification emphasizes the importance of effective nutrition and supplementation strategies to optimize human performance, recovery, and the overall health of athletes and active individuals. In addition, Jun had the opportunity to attend the 20th

anniversary of the ISSN conference held in the city of Fort Lauderdale, Florida on behalf of ChromaDex. The ISSN conference attracted a diverse range of attendees – including professors, post-doctoral scholars, undergraduate and graduate students, practitioners, and industry professionals – fostering a lively environment of stimulating intellectual exchange. During the conference, there were thought-provoking discussions with researchers who expressed interest in the application of NAD precursor supplements in exercise performance and recovery to support athletes and active individuals. The potential additive and synergistic effects of combining nicotinamide riboside with other sport nutrition ingredients were also discussed. The conference proved to be an enriching experience with countless networking opportunities and educational sessions with cutting-edge insights into the latest and greatest in sport science, supplementation, and nutrition.

Come See Us At Our Booth



P11-034-23



P11-036-23



Celebrating 10 Years
of Leading NAD+ Research with CERP

Interested in learning more about how to develop intellectual property that industry would want to license or how to commercialize your ideas?

If so, ChromaDex has a dynamic Business Development Team that would love to talk with you. For more information, send an email to cerp@chromadex.com with the subject line: Business Development, and we will get you connected.

Expand Your NAD+ Research Portfolio by including rarely studied NAD+ precursors. For more information send an email to cerp@chromadex.com with the subject line: Novel NAD+ Precursors.

CERPI Communiqué, Volume 4, Issue 2, June 2023



ChromaDex External Research Program

ChromaDex, Inc.
10900 Wilshire Boulevard, Suite 600
Los Angeles, California, USA 90024
+1 (310) 388-6706
cerp@chromadex.com
<http://www.chromadex.com/cerp>

Setting the Industry Standard for Excellence in Collaborative Research

Special thanks to our CERPI Communiqué content contributors, editors, and reviewers:

Rebecca Idoine
Jun Kwon
Yasmeen Nkrumah-Elie, PhD
Andrew Shao, PhD
Heather Van Blarcom, JD